| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1474-4422(09)70239-X |
| P698 | PubMed publication ID | 19783216 |
| P50 | author | Bob Siegerink | Q41105762 |
| Ale Algra | Q58370115 | ||
| Rolf T. Urbanus | Q79346608 | ||
| P2093 | author name string | Philip G de Groot | |
| Frits R Rosendaal | |||
| Mark Roest | |||
| P2860 | cites work | International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) | Q28292418 |
| Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study | Q28368332 | ||
| Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients | Q33341941 | ||
| Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) study: oral contraceptives and the risk of ischemic stroke | Q34126604 | ||
| Mutation in blood coagulation factor V associated with resistance to activated protein C. | Q34340007 | ||
| The pathophysiology of cigarette smoking and cardiovascular disease: an update | Q34547935 | ||
| Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature | Q34977289 | ||
| Current insight into diagnostics and pathophysiology of the antiphospolipid syndrome. | Q36982870 | ||
| Coagulation factor XIII gene variation, oral contraceptives, and risk of ischemic stroke | Q38459631 | ||
| Prothrombotic conditions, oral contraceptives, and the risk of ischemic stroke | Q38473692 | ||
| Oral contraceptives and the risk of myocardial infarction | Q38491037 | ||
| Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). | Q40371426 | ||
| Anticardiolipin antibodies and risk of ischemic stroke and transient ischemic attack: the Framingham cohort and offspring study | Q40533021 | ||
| Inhibition of APC anticoagulant activity on oxidized phospholipid by anti-{beta}2-glycoprotein I monoclonal antibodies | Q42742480 | ||
| Antiphospholipid antibodies and stroke in young women | Q44168396 | ||
| beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome | Q45021710 | ||
| Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). | Q46522917 | ||
| High-risk myocardial infarction in the young: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial | Q46678648 | ||
| Are changes in mortality from stroke caused by changes in stroke event rates or case fatality? Results from the WHO MONICA Project | Q47766323 | ||
| The frequency of phospholipid antibodies in an unselected stroke population | Q48494425 | ||
| Anti-beta 2 glycoprotein I antibodies and the risk of myocardial infarction in young premenopausal women | Q61040663 | ||
| Anticardiolipin antibodies as a risk factor for venous thromboembolism in a population-based prospective study | Q61768913 | ||
| Anticardiolipin antibodies in acute non-hemorrhagic stroke seen within six hours after onset | Q71773088 | ||
| Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men | Q72369034 | ||
| Risk of stroke in young women and two prothrombotic mutations: factor V Leiden and prothrombin gene variant (G20210A) | Q74324113 | ||
| Lupus anticoagulants and the risk of a first episode of deep venous thrombosis | Q81064718 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | myocardial infarction | Q12152 |
| antibody | Q79460 | ||
| P304 | page(s) | 998-1005 | |
| P577 | publication date | 2009-09-25 | |
| P1433 | published in | Lancet Neurology | Q15755067 |
| P1476 | title | Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study | |
| P478 | volume | 8 |
| Q35250419 | "New" antigenic targets and methodological approaches for refining laboratory diagnosis of antiphospholipid syndrome |
| Q37838098 | 'Criteria' aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, Texas, April 2010. |
| Q37790448 | A review of hereditary and acquired coagulation disorders in the aetiology of ischaemic stroke |
| Q35539166 | Accelerated vascular disease in systemic lupus erythematosus: role of macrophage |
| Q92797128 | Acute ST-elevation myocardial infarction in a young patient with antiphospholipid syndrome |
| Q35997177 | Acute coronary syndromes in young women - the scale of the problem and the associated risks |
| Q37802044 | Aetiological diagnosis of ischaemic stroke in young adults |
| Q38885685 | Anti-phospholipid Antibodies and Smoking: An Overview |
| Q53399550 | Anti-β2 glycoprotein I antibodies in complex with β2 glycoprotein I induce platelet activation via two receptors: apolipoprotein E receptor 2' and glycoprotein I bα. |
| Q90312460 | Antiphospholipid Syndrome and Kidney Involvement: New Insights |
| Q48443751 | Antiphospholipid antibodies correlate with stroke severity and outcome in patients with antiphospholipid syndrome |
| Q96960258 | Antiphospholipid antibodies in patients with COVID-19: a relevant observation? |
| Q48448846 | Antiphospholipid antibodies: pinning risk on a moving target |
| Q50954058 | Antiphospholipid antibody testing - slow progress? |
| Q55891386 | Antiphospholipid syndrome |
| Q64046338 | Antiphospholipid syndrome |
| Q34307502 | Antiphospholipid syndrome and the brain in pediatric and adult patients |
| Q38596401 | Antiphospholipid syndrome presenting as cerebral venous sinus thrombosis: a case series and a review |
| Q44719836 | Antiphospholipid syndrome: interpretation of laboratory data |
| Q36337350 | Antiphospholipid-related chorea. |
| Q60907847 | Are serum autoantibodies associated with brain changes in systemic lupus erythematosus? MRI data from the Leiden NP-SLE cohort |
| Q37058062 | Arterial ischemic stroke in HIV: Defining and classifying etiology for research studies |
| Q37063656 | Assessment of the independent associations of IgG, IgM and IgA isotypes of anticardiolipin with thrombosis in SLE. |
| Q39502759 | Association between antiphospholipid antibodies and arterial thrombosis in patients with rheumatoid arthritis |
| Q53131881 | Association of arterial events with the coexistence of metabolic syndrome and primary antiphospholipid syndrome. |
| Q37824302 | Auto-antibodies as emergent prognostic markers and possible mediators of ischemic cardiovascular diseases |
| Q64262888 | Cardiac Manifestations of Antiphospholipid Syndrome With Focus on Its Primary Form |
| Q36355415 | Cardiac manifestations of rheumatological conditions: a narrative review |
| Q36995139 | Cardiovascular disease and cognitive dysfunction in systemic lupus erythematosus |
| Q36303250 | Cardiovascular risk factors are major determinants of thrombotic risk in patients with the lupus anticoagulant |
| Q45843374 | Cigarette smoking, antiphospholipid antibodies and vascular events in Systemic Lupus Erythematosus |
| Q38657043 | Clinical Risk Assessment in the Antiphospholipid Syndrome: Current Landscape and Emerging Biomarkers |
| Q24187746 | Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke |
| Q64092966 | Complement in the Pathophysiology of the Antiphospholipid Syndrome |
| Q38818425 | Current status and future prospects for the treatment of antiphospholipid syndrome |
| Q37853050 | Cutting-edge issues in coronary disease and the primary antiphospholipid syndrome |
| Q47982275 | Diagnosis and management of the antiphospholipid syndrome |
| Q33421814 | Difficult clinical situations in the antiphospholipid syndrome |
| Q37721607 | Domain I of beta2-glycoprotein I: its role as an epitope and the potential to be developed as a specific target for the treatment of the antiphospholipid syndrome |
| Q33731711 | EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome |
| Q56531006 | Evaluation of antiphospholipid antibodies in youths suffering from cerebral ischemia |
| Q37705853 | Factor V Leiden does not have a role in cryptogenic ischemic stroke among Iranian young adults |
| Q38860396 | Factor XII: form determines function |
| Q22306331 | Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association |
| Q22306361 | Guidelines for the Prevention of Stroke in Women: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association |
| Q37982121 | Guidelines on the investigation and management of antiphospholipid syndrome |
| Q43714467 | High-molecular-weight kininogen and the risk of a myocardial infarction and ischemic stroke in young women: the RATIO case-control study |
| Q40039972 | Hormonal contraception and the development of autoimmunity: A review of the literature |
| Q47142161 | Hormonal contraceptives and risk of ischemic stroke in women with migraine: a consensus statement from the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC). |
| Q33393146 | Hughes syndrome (the antiphospholipid syndrome): a disease of our time |
| Q40732678 | Hypercoagulability and the risk of myocardial infarction and ischemic stroke in young women. |
| Q64119237 | Hypercoagulability and the risk of recurrence in young women with myocardial infarction or ischaemic stroke: a cohort study |
| Q90115791 | Idiopathic Normal Pressure Hydrocephalus - What We Know |
| Q38591312 | Incidence, pathophysiology, and clinical manifestations of antiphospholipid syndrome. |
| Q41200243 | Increased heterogeneity of brain perfusion is an early marker of central nervous system involvement in antiphospholipid antibody carriers. |
| Q57983447 | Induction of anti-β2-glycoprotein I autoantibodies in mice by protein H of Streptococcus pyogenes |
| Q45771233 | Influence of antiphospholipid antibody levels and type on thrombotic manifestations: results from the Serbian National Cohort Study |
| Q38207855 | Ischaemic stroke in young adults: risk factors and long-term consequences. |
| Q64892470 | Ischemic stroke in the young: Current perspectives on incidence, risk factors, and cardiovascular prognosis. |
| Q46339090 | Long-term outcome of patients with antiphospholipid syndrome who undergo percutaneous coronary intervention |
| Q51332462 | Lupus anticoagulant: a marker for stroke and venous thrombosis in primary Sjögren's syndrome. |
| Q38180647 | Management of recurrent thrombosis in antiphospholipid syndrome |
| Q83286175 | Mechanisms of anti-phospholipid antibody formation and action |
| Q37903952 | Molecular pathophysiology of the antiphospholipid syndrome: the role of oxidative post-translational modification of beta 2 glycoprotein I. |
| Q44030345 | National registry-based case-control study: comorbidity and stroke in young adults. |
| Q33389669 | Nephritis and the risk of acute myocardial infarction in patients with systemic lupus erythematosus |
| Q53096115 | Neurological presentations of the antiphospholipid syndrome: three illustrative cases. |
| Q51251394 | Neuropsychiatric Lupus in clinical practice. |
| Q37810821 | New Insights into the Biology and Pathobiology of Beta2-Glycoprotein I |
| Q97886328 | No Association between Ischemic Stroke and Portal Vein Thrombosis in Liver Cirrhosis |
| Q35895238 | Novel assays of thrombogenic pathogenicity in the antiphospholipid syndrome based on the detection of molecular oxidative modification of the major autoantigen β2-glycoprotein I. |
| Q58551653 | Obstetric antiphospholipid syndrome |
| Q38658401 | Obstetric antiphospholipid syndrome and long term arterial thrombosis risk |
| Q38230699 | Pathogenesis and treatment of atherosclerosis in lupus |
| Q38156069 | Pragmatic approaches to therapy for systemic lupus erythematosus |
| Q90115787 | Pregnancy Management in Women with Antiphospholidic Syndrome |
| Q40809455 | Pregnancy loss and risk of ischaemic stroke and myocardial infarction |
| Q38794847 | Prevention of Recurrent Thrombosis in Antiphospholipid Syndrome: Different from the General Population? |
| Q39027911 | Prevention of thrombosis in antiphospholipid syndrome |
| Q42670330 | Prothrombin G20210A (rs1799963) polymorphism increases myocardial infarction risk in an age-related manner: A systematic review and meta-analysis |
| Q33724615 | Prothrombin G20210A mutation is associated with young-onset stroke: the genetics of early-onset stroke study and meta-analysis |
| Q54266701 | Prothrombotic factors do not increase the risk of recurrent ischemic events after cryptogenic stroke at young age: the FUTURE study. |
| Q30701440 | Reversible cerebral vasoconstriction syndrome (RCVS) in antiphospholipid antibody syndrome (APLA): the role of centrally acting vasodilators. Case series and review of literature |
| Q33692770 | Review on Effectiveness of Primary Prophylaxis in aPLs with and without Risk Factors for Thrombosis: Efficacy and Safety |
| Q34472618 | Risk factors for ischemic stroke and transient ischemic attack in patients under age 50 |
| Q38019658 | Risk of vascular disease in patients with multiple sclerosis: a review |
| Q34573328 | Role of investigating thrombophilic disorders in young stroke. |
| Q37775992 | Screening for coagulation disorders in patients with ischemic stroke |
| Q37868357 | Stroke in young women. |
| Q38873953 | The antiphospholipid syndrome: from pathophysiology to treatment. |
| Q36928593 | The antiphospholipid syndrome: still an enigma |
| Q38703934 | The challenges of lupus anticoagulants |
| Q38125246 | The current standing of diagnosis of antiphospholipid syndrome associated with systemic lupus erythematosus |
| Q38221324 | The estimated frequency of antiphospholipid antibodies in young adults with cerebrovascular events: a systematic review |
| Q37959884 | The management of stroke in antiphospholipid syndrome |
| Q48286100 | Thrombophilia in 153 Patients With Premature Cardiovascular Disease ≤Age 45. |
| Q33406643 | Thrombotic risk in patients with immune thrombocytopenia and its association with antiphospholipid antibodies |
| Q38205955 | Tracking down contact activation - from coagulation in vitro to inflammation in vivo. |
| Q35648075 | Treatment of risk factors to prevent stroke |
| Q90416101 | [Antiphospholipid syndrome : Update on diagnostics and management] |
Search more.